The DEA Telehealth Prescribing Deadline: What Expires December 31, 2026 and How to Prepare

December 31, 2026. That is the date the current telemedicine prescribing flexibilities are set to lapse, and it is close enough now that it should be in your operating plan rather than your watch list.

What is expiring, exactly?

Since 2020, DEA-registered practitioners have been allowed to prescribe Schedule II through V controlled substances via telemedicine without first conducting an in-person medical evaluation. That is an exception to the Ryan Haight Act of 2008, which otherwise requires an in-person exam before a controlled substance prescription.

The exception has never been permanent. It has been extended four times. The most recent extension was published in the Federal Register on December 31, 2025, is effective from January 1, 2026, and runs through December 31, 2026.

What replaces it?

The intended replacement is a permanent framework called Special Registrations for Telemedicine and Limited State Telemedicine Registrations. DEA published it as a proposed rule in January 2025. It has not been finalized.

DEA has listed the final rule in the Unified Regulatory Agenda as expected in November 2026. That would leave roughly six weeks between publication and the expiry of the current flexibilities.

As proposed, the framework would create special registration categories for prescribers, require registration for telemedicine platforms that facilitate prescribing, and add obligations around prescription drug monitoring program checks, audio-video requirements, identity verification, clinician credentialing, data reporting to DEA, and record retention. Schedule II prescribing would carry additional restrictions.

None of that is settled. The proposal drew substantial comment and the agency has not indicated what the final version will contain.

What are the actual scenarios?

Three, and they are worth planning against separately.

A final rule lands late in 2026 and a new registration regime begins. This is the stated plan. It means a compliance build with very little runway, since registration, recordkeeping and security requirements would all need to be operational.

A fifth temporary extension is issued. This is what happened at the end of each of the previous four years. It is the outcome most operators are quietly assuming.

Neither happens before December 31. In that case the Ryan Haight in-person requirement returns for new patients, which for a virtual-first prescribing model is not a compliance inconvenience but a break in the service.

What should an operator do now?

Know which of your patients are affected. The requirement attaches to patients who have never had an in-person evaluation with the prescriber. If you can already produce that segmentation, you are ahead of most.

Confirm your prescribers' DEA registrations and state controlled substance registrations are current and mapped to the states you serve. These are separate from medical licensure and they lapse independently.

Work out what an in-person requirement would actually cost your model. For some operators it means a referral relationship with in-person sites. For others it means the product does not function. Knowing which one you are is the planning input that matters.

Watch the Federal Register rather than the trade press. The four previous extensions were published there first.

What this is not

This is a federal prescribing question, and it sits on top of state law rather than replacing it. State controlled substance rules, state telehealth requirements, and state licensure all continue to apply independently. A federal flexibility does not authorize prescribing in a state where the clinician is not licensed.

Frequently asked questions

When do the DEA telehealth prescribing flexibilities expire?December 31, 2026. DEA and HHS published a fourth temporary extension in the Federal Register on December 31, 2025, effective January 1, 2026 and running through the end of that year.

What do the flexibilities currently allow?DEA-registered practitioners may prescribe Schedule II through V controlled substances via telemedicine without first conducting an in-person medical evaluation. This is an exception to the Ryan Haight Act of 2008, which otherwise requires an in-person exam before a controlled substance prescription.

What is the Special Registration rule?A proposed permanent framework, published by DEA in January 2025 and not yet finalized, called Special Registrations for Telemedicine and Limited State Telemedicine Registrations. As proposed it would create special registration categories for prescribers, require telemedicine platforms to register, and add requirements around prescription drug monitoring checks, audio-video use, identity verification, clinician credentialing, data reporting and record retention.

When is the final rule expected?DEA has listed it in the Unified Regulatory Agenda as expected in November 2026, which would leave roughly six weeks before the current flexibilities lapse. The agency has not indicated what the final rule will contain.

What happens if no rule or extension is issued?The Ryan Haight in-person evaluation requirement would return for patients who have never been examined in person by the prescriber. For a virtual-first prescribing model that is a break in the service rather than a compliance adjustment.

Does a federal flexibility remove state requirements?No. State controlled substance rules, state telehealth requirements and state licensure all apply independently. A federal prescribing flexibility does not authorize practice in a state where the clinician is not licensed.

DirectShifts handles multi-state licensing and clinician supply for virtual care operators, so prescriber coverage stops waiting on paperwork. Tell us which states you are trying to reach.